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Introduction {#sec1}
============

Cell therapy using hepatocytes has been highlighted as a promising treatment for repairing the irreversible liver diseases as an alternative to liver transplantation ([@bib5], [@bib8]). However, due to the limited accessibility and non-expandable nature of primary hepatocytes, a number of studies have attempted to generate hepatocyte-like cells from distinct types of stem cells, such as pluripotent stem cells (PSCs) ([@bib10], [@bib11], [@bib31], [@bib39]). Indeed, hepatocyte-like cells generated from PSCs clearly share the key cellular features of primary hepatocytes ([@bib10], [@bib31]), but ethical and safety concerns abound on the use of PSC-derived hepatocyte-like cells in the clinic ([@bib32]). To obviate the issues associated with using PSC-derived hepatocyte-like cells, recent studies directly generated hepatocyte-like cells, namely iHeps (induced hepatocyte-like cells), from both mouse and human somatic cells with defined factors without the cells having to first pass through a PSC state ([@bib6], [@bib12], [@bib13], [@bib15], [@bib21], [@bib30]).

Recent studies have demonstrated that the relatively small population of non-parenchymal cell types, such as cholangiocytes, plays also an important role in liver regeneration ([@bib2], [@bib36]). Recently developed direct conversion technology has been applied for generating self-renewing and bipotential HepSCs, so-called induced hepatic stem-like cells (iHepSCs), using the defined factors *Hnf1β* and *Foxa3* ([@bib38]). But prior to the translation of iHepSC technology to the clinic, a few issues need clear resolution. First, the final factor combination for iHepSC generation was determined without considering the actual conversion efficiency using authentic HepSC-specific markers. Second, the efficiency of converting somatic cells into iHepSCs is very low, less than 0.5%, and needs to be improved. Third, and most importantly, iHepSCs exhibit very low differentiation potential into mature cholangiocytes, which strongly necessitates further optimization of the combination of factors used for obtaining either iHepSCs with enhanced cholangiocyte differentiation potential or cholangiocyte progenitor cells (CPCs).

In the current study, we revisited the roles of several HepSC-specific candidate factors in reprogramming and found that the combination of *Hnf1α* and *Foxa3* dramatically facilitates the generation of iHepSCs that are transcriptionally closer to the endogenous hepatic progenitor cells than are iHepSCs from previous study. Moreover, the prolonged culture of *Hnf1α* and *Foxa3-*derived iHepSCs could induce further reprogramming that is mediated by Notch signaling into cholangiocyte progenitor-like cells, so-called induced CPCs (iCPCs), which display dramatically enhanced differentiation potential into mature cholangiocytes. Our study provides a strategy for generating iCPCs using defined factors.

Results {#sec2}
=======

*Hnf1α* and *Foxa3* Robustly Induce Hepatic Stemness in Fibroblasts {#sec2.1}
-------------------------------------------------------------------

To define the combination of factors that is required for inducing either HepSC or CPC identities in somatic cells, we selected five candidate factors based on their roles in liver development (*Foxa1*, *Foxa2*, and *Hnf1β*) and regeneration (*Foxa3* and *Hnf1α*). Mouse embryonic fibroblasts (MEFs), which are devoid of epithelial cells, were transduced with all candidate factors as described previously ([@bib21]) ([Figure 1](#fig1){ref-type="fig"}A). After 2 weeks of transduction, we observed the growth of epithelial colonies of a compact and three-dimensional (3D) shape that was morphologically distinct from that typical of iHep colonies ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Notably, a significant number of colonies expressed both the fetal hepatocyte marker α-fetoprotein (AFP) and the cholangiocyte marker cytokeratin 19 (CK19) (67.5% ± 13.5%; [Figures 1](#fig1){ref-type="fig"}B and 1C). Moreover, these colonies were strongly positive for other cholangiocyte and HepSC markers, such as CK7 and TROP2, respectively ([Figure 1](#fig1){ref-type="fig"}B). However, partially reprogrammed cells with epithelial morphology failed to activate both AFP and CK19 ([Figure S1](#mmc1){ref-type="supplementary-material"}B), indicating that our unbiased approach could accurately measure the conversion efficiency. Taken together, the epithelial colonies that had emerged from the five factor-transduced MEFs might have a cellular identity similar to HepSCs and distinct from iHeps.Figure 1Direct Conversion of Fibroblasts into iHepSCs by *Hnf1α* and *Foxa3*(A) Schematic depicting the procedure for the direct conversion of fibroblasts into iHepSCs.(B) Immunofluorescence of iHepSC colony after 2 weeks of transducing all five transcription factors. Nuclei were stained with DAPI. Scale bars, 100 μm.(C) The number of AFP^+^/CK19^+^ colonies was counted after 2 weeks of transduction. Data are presented as mean ± SD from three independent experiments. Two-tailed Student's t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01.(D and E) Expression patterns of hepatocyte-, cholangiocyte-, and HepSC-specific markers were analyzed by RT-PCR after transduction of MEFs with different combinations of factors.(F) The number of AFP^+^/CK19^+^ colonies was counted on day 14 post transduction of MEFs with *Hnf1α* together with *Foxa2* (1a2) or *Foxa3* (1a3). Data are presented as mean ± SD from three independent experiments. Two-tailed Student's t test: ^∗^p \< 0.05.(G) Immunofluorescence of 1a3-transduced iHepSC colony. The nuclei were stained with DAPI. Scale bars, 100 μm.(H) Percentage of EPCAM^+^ cells was evaluated by flow cytometry 2 weeks after transduction of MEFs with either 1a2 or 1a3. MEFs, i.e., non-transduced cells, were used as a negative control. Data are presented as mean ± SD from three independent experiments. Two-tailed Student's t test: ^∗^p \< 0.05.(I) Expression of hepatocyte-, cholangiocyte-, and HepSC-specific markers in EPCAM^+^ or EPCAM^−^ cells was measured by qPCR. The levels were normalized to those of EPCAM^+^ cells and are presented as mean ± SD from triplicate values.

We next attempted to minimize the number of factors required for iHepSC conversion. For this, we removed the factors from the cocktail one by one and found that removing any of the three factors *Foxa2*, *Foxa3*, and *Hnf1α* drastically reduced the number of AFP^+^/CK19^+^ iHepSC colonies ([Figure 1](#fig1){ref-type="fig"}C). The removal of either *Hnf1β* or *Foxa1* did not negatively influence both iHepSC conversion and hepatic gene activation ([Figures 1](#fig1){ref-type="fig"}C and 1D). In contrast, iHepSCs generated in the absence of *Hnf1α* displayed poor activation of endogenous HepSC markers ([Figure 1](#fig1){ref-type="fig"}D). However, the gene expression pattern of iHepSCs generated in the absence of either *Foxa2* or *Foxa3* was comparable with that of iHepSCs generated with all five factors together ([Figure 1](#fig1){ref-type="fig"}D). Thus, we hypothesized that *Hnf1α* might play a key role in the transcriptional activation of the endogenous hepatic program and that *Foxa2* and *Foxa3* might rather play assistant roles that would enhance the conversion efficiency ([Figures 1](#fig1){ref-type="fig"}C and 1D). To test our hypothesis, we introduced *Hnf1α* with either *Foxa2* (1a2) or *Foxa3* (1a3) in MEFs. Interestingly, 1a3-transduced MEFs exhibited the more mature expression patterns of both cholangiocyte (*CK7* and *CK19*) and HepSC (*Epcam* and *Trop2*) markers ([Figure 1](#fig1){ref-type="fig"}E) with significantly higher numbers of AFP^+^/CK19^+^ iHepSC colonies ([Figure 1](#fig1){ref-type="fig"}F) than did 1a2-transduced MEFs. The majority of 1a3-derived iHepSC colonies were strongly double-positive for other hepatocyte and cholangiocyte markers ([Figure 1](#fig1){ref-type="fig"}G). Notably, 1a3-transduced MEFs produced a significantly higher number of EPCAM^+^ cells strongly expressing hepatocyte-, cholangiocyte-, and HepSC-specific markers ([Figures 1](#fig1){ref-type="fig"}H and 1I). All the clonal lines derived from 1a3-transduced MEFs displayed the features typical of HepSCs as determined by a series of gene expression analyses ([Figures S1](#mmc1){ref-type="supplementary-material"}C--S1E). Finally, iHepSCs could be generated from mouse adult tail-tip fibroblasts and were stably expanded for more than 10 passages without losing features typical of HepSCs ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Notably, three-factor (*Hnf1α*, *Foxa2*, and *Foxa3*; 1a23) could not further enhance reprogramming efficiency compared with 1a3 ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Taken together, our data clearly show that 1a3 is the best combination for a robust induction of hepatic stemness on somatic cells but is not enough for inducing a CPC cell identity.

1a3-iHepSCs Can Differentiate into Mature Hepatocytes and Cholangiocytes *In Vitro* {#sec2.2}
-----------------------------------------------------------------------------------

We next assessed the *in vitro* differentiation potential of 1a3-derived iHepSCs (hereafter referred to as 1a3-iHepSCs) to determine whether they had acquired hepatic stemness. Within 24 hr of hepatic differentiation ([@bib20], [@bib38]), aggregates typical of differentiated cells were readily observed ([Figure S2](#mmc1){ref-type="supplementary-material"}A). After 7 days, we were able to identify mature aggregates with strong activation of albumin (ALB) and complete inactivation of CK19 ([Figure 2](#fig2){ref-type="fig"}A). RT-PCR analysis also showed that the expression of hepatocyte markers was strongly upregulated, whereas both cholangiocyte and HepSC markers were dramatically suppressed ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Moreover, 1a3-iHepSCs were found to display glycogen storage, xenobiotic metabolic activity, and albumin secretion upon hepatic differentiation, indicating that they have the potential to differentiate into mature hepatocytes *in vitro* ([Figures 2](#fig2){ref-type="fig"}B and 2C).Figure 2Differential Potential of 1a3-iHepSCs into Mature Hepatocytes and Cholangiocytes *In Vitro*(A) Immunofluorescence of established 1a3-iHepSC-derived hepatocytes. The nuclei were stained with DAPI. Scale bar, 100 μm.(B) *In vitro* functional analyses of 1a3-iHepSC--derived hepatocytes by periodic acid-Schiff (PAS) staining and indocyanine green (ICG) uptake assay. Scale bars, 100 μm.(C) Serum albumin secreted from 1a3-iHepSC-derived hepatocytes was measured by ELISA. MEFs and primary hepatocytes were used as negative and positive controls, respectively. Data are presented as mean ± SD from triplicate values.(D) Morphology of 1a3-iHepSC--derived cholangiocytes in branches and ductal cysts was analyzed under bright-field (upper panel) and immunofluorescence (lower panel) microscopy. Antibody directed against CK19 was used, and the nuclei were stained with DAPI. Scale bar, 100 μm.(E) Expression of mature cholangiocyte markers was evaluated by qPCR upon cholangiocyte differentiation. All the values were normalized to those of undifferentiated 1a3-iHepSCs. Bile duct tissues were used as a positive control. Data are presented as mean ± SD of triplicate values from three individual cell lines. Two-tailed Student's t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01.(F) Transport of rhodamine-123 (Rho123) into the central lumen of a ductal cyst. Treatment with the MDR inhibitor verapamil (Ver) to block the transport activity of 1a3-iHepSC-derived ductal cysts. Scale bar, 100 μm.(G) Quantification of degree of cyst swelling of 1a3-iHepSC--derived cholangiocytes after 24 hr of stimulation with forskolin (FSK) and IBMX in the absence or presence of the CFTR inhibitor CFTR^inh^-172. The degree of swelling after 24 hr of stimulation was quantified based on the unstimulated cyst size. Five cysts in each group from three independent experiments were analyzed. Data are presented as mean ± SD. Paired t test: ^∗^p \< 0.05.

After 7 days of differentiation into cholangiocytes ([@bib19]), 1a3-iHepSCs had differentiated into CK19^+^ cholangiocytes that exhibited a typical branching structure ([Figure 2](#fig2){ref-type="fig"}D, left). Under 3D differentiation conditions containing 40% Matrigel ([@bib33]), we observed CK19^+^ mature cystic structures ([Figure 2](#fig2){ref-type="fig"}D, right). The cysts strongly expressed cholangiocyte-associated genes ([Figure 2](#fig2){ref-type="fig"}E) and exhibited apicobasal polarity as shown by the localization of F-actin in the inner layer of the lumen ([Figure S2](#mmc1){ref-type="supplementary-material"}C), demonstrating that cholangiocytes that had differentiated from 1a3-iHepSCs share molecular and structural characteristics with primary cholangiocytes. A major physiological function of cholangiocytes is the secretion of substances such as water and ions for modulating bile composition, and this process is mediated by transmembrane channel proteins such as multidrug resistance protein 1 (MDR1) and cystic fibrosis transmembrane regulator (CFTR). Thus, we examined the transporter activity of MDR1 in the cholangiocytes derived from 1a3-iHepSCs by evaluating the efflux of rhodamine-123 (Rho123), and found that the cholangiocytes could transport Rho123 into the luminal space ([Figure S2](#mmc1){ref-type="supplementary-material"}D). However, in the presence of the MDR1 inhibitor verapamil, Rho123 did not accumulate in the lumen, indicating that the differentiated cholangiocytes in cysts behave like their *in vivo* counterpart ([Figure 2](#fig2){ref-type="fig"}F). We also performed a forskolin-induced swelling assay to monitor CFTR-mediated fluid transport and cyst swelling in the cholangiocytes. After 24 hr of forskolin treatment, the size of the cysts had increased by 3.31 ± 0.44-fold ([Figures 2](#fig2){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}E). In contrast, the forskolin/IBMX (3-isobutyl-1-methylxanthine)-induced cyst swelling was abolished in the presence of CFTR^inh^-172, a CFTR inhibitor, showing that the size of the cysts that had differentiated from 1a3-iHepSCs is regulated by CFTR, as in *in vivo* cholangiocytes ([Figure 2](#fig2){ref-type="fig"}G). Notably, iHepSCs from adult tail-tip fibroblasts also differentiated into both hepatocytes and cholangiocytes ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G). Taken together, our data clearly indicate that 1a3-iHepSCs possess an *in vitro* differentiation potential into both functionally mature hepatocytes and cholangiocytes.

*Hnf1α* Plays a Critical Role in the Induction Phase of Hepatic Stemness Acquisition {#sec2.3}
------------------------------------------------------------------------------------

As the previous study ([@bib38]) had used *Hnf1β* and *Foxa3* (1b3) for converting fibroblasts into iHepSCs, we decided to compare the roles of the two reprogramming cocktails 1a3 and 1b3 during the induction phase of hepatic stemness acquisition ([Figure 3](#fig3){ref-type="fig"}A). In line with our screening assay results ([Figure 1](#fig1){ref-type="fig"}), 1a3-transduced MEFs produced significantly increased numbers of either E-cadherin^+^ or EPCAM^+^ populations compared with the 1b3-transduced MEFs ([Figure 3](#fig3){ref-type="fig"}B). This increased yield of 1a3 was due to neither distinct transduction levels of individual transgenes nor distinct proliferation rates of the MEFs transduced with distinct combinations of factors ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Notably, 1a3-transduced MEFs exhibited dramatically accelerated conversion kinetics toward a HepSC state, as evidenced by the enhanced activation of genes associated with hepatic stemness compared with 1b3-transduced MEFs ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#mmc1){ref-type="supplementary-material"}C). Taken together, these data suggest that a conversion cocktail 1a3 is more potent than 1b3 for the robust induction of hepatic stemness.Figure 3*Hnf1α* Plays a Critical Role in the Induction Phase of Hepatic Stemness Acquisition(A) Schematic comparing the direct conversion process of fibroblasts into iHepSCs driven by *Foxa3* together with *Hnf1α* (1a3) or *Hnf1β* (1b3).(B) Conversion efficiency (%) into iHepSCs from the MEFs transduced with either 1a3 or 1b3 was determined by flow-cytometric analysis using an antibody directed against E-cadherin (left) or EPCAM (right) on day 14 of transduction.(C) Expression of hepatocyte-, cholangiocyte-, and HepSC-specific markers was analyzed by qPCR in a time course manner after transduction of MEFs with each reprogramming cocktail. The levels were normalized to those of MEFs and are presented as mean ± SD of triplicate values.(D) Heatmaps representing the expression patterns of markers related to mesenchymal-epithelial transition (MET) process, fibroblasts, cell cycle, hepatocytes, cholangiocytes, and hepatic progenitors after 12 days of introducing 1a3 or 1b3 into MEFs. Color bar at the bottom indicates gene expression in log~2~ scale. Red and green colors represent higher and lower expression levels, respectively.(E) TRNs in the MEFs after 12 days of transducing MEFs with 1a3 or 1b3. Subnetwork modules were extracted using DEGs between LEPCs and MEFs by CellNet. Yellow and red dashed circles represent MEF- and LEPC-specific modules, respectively.(F) Heatmaps describing gene expression profiles in LEPC- and MEF-specific modules in MEFs 12 days post infection with 1a3 or 1b3. Hierarchical clustering analysis based on the gene expression profiles from the heatmap is shown at the top. MEFs and LEPCs were used as negative and positive controls, respectively.

To explore the mechanism underlying 1a3-mediated enhanced iHepSC generation, we monitored the early transcriptional changes taking place following the introduction of 1a3 or 1b3 to the cells. Whole-genome transcription analysis revealed that a similar number of genes was either up- or downregulated ([Figure S3](#mmc1){ref-type="supplementary-material"}D), and that both combinations activated similar pathways involved in various metabolic functions of the liver ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Despite this high similarity ([Figure S3](#mmc1){ref-type="supplementary-material"}F), we found that 441 and 357 genes were highly enriched in 1a3- and 1b3-transduced MEFs, respectively ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Gene ontology (GO) analysis of differentially expressed genes (DEGs) from 1a3- and 1b3-transduced MEFs (1a3-DEGs and 1b3-DEGs) show that various metabolic processes were highly ranked in 1a3-DEGs, whereas the genes involved in cell adhesion and neuronal development were top-ranked in 1b3-DEGs ([Figure S3](#mmc1){ref-type="supplementary-material"}H). These data underscore the notion that 1b3 could not sufficiently activate the HepSC program and has off-target effects, activating genes associated with ectoderm lineage.

We next investigated the transcriptional signatures of 1a3-and 1b3-transduced MEFs by comparing the cells\' transcriptional regulatory network (TRN). To this end, we employed CellNet ([@bib3]), a computational network biology platform providing a comprehensive description of transcriptional networks constructed by numerous interactions among highly ranked transcription factors. We first generated a HepSC-TRN using both mouse liver epithelial progenitor cells (LEPCs)-specific DEGs ([@bib20]) and MEF-specific DEGs ([Figure S3](#mmc1){ref-type="supplementary-material"}H). We found two major distinct subnetwork modules in the HepSC-TRN that are specific to LEPCs and MEFs, respectively ([Figures S3](#mmc1){ref-type="supplementary-material"}I and S3J). To evaluate the early reprogramming status of both 1a3- and 1b3-transduced MEFs, we applied the DEGs (1a3 versus MEFs and 1b3 versus MEFs) on the HepSC-TRN ([Figure 3](#fig3){ref-type="fig"}E). In line with our kinetic analysis results ([Figures 3](#fig3){ref-type="fig"}C and 3D), 1a3-transduced MEFs displayed faster activation of genes involved in the LEPC-specific module compared with 1b3-transduced MEFs ([Figure 3](#fig3){ref-type="fig"}F). These data support the notion that *Hnf1α* is the authentic driving force for inducing hepatic stemness.

1a3-iHepSCs Are Transcriptionally Closer Than 1b3-iHepSCs to LEPCs {#sec2.4}
------------------------------------------------------------------

To compare the molecular and cellular characteristics of the established 1a3-iHepSCs with those of 1b3-iHepSCs, we generated three clonal iHepSC lines from each combination. During clonal expansion, we were unable to observe any significant difference in the proliferation rate and clonal efficiency of the resultant iHepSCs, indicating that the self-renewal capacities of both 1a3- and 1b3-iHepSCs are comparable ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Notably, the majority of stem cell markers were strongly activated in all 1a3-iHepSC clones, whereas some epithelial and HepSC markers were relatively less activated in most 1b3-iHepSC lines ([Figure 4](#fig4){ref-type="fig"}A). Heatmap analysis also showed that 1a3-iHepSCs displayed the relatively well-reprogrammed pattern of gene transcription compared with the expression pattern of 1b3-iHepSCs, although these cells clustered together ([Figure 4](#fig4){ref-type="fig"}B). Particularly, the fibroblast-specific transcriptional signature was largely maintained in the established 1b3-iHepSCs but nearly erased in 1a3-iHepSCs ([Figure 4](#fig4){ref-type="fig"}B), indicating that *Hnf1α* plays a critical role not only in the induction phase but also in the maturation phase of the process of acquiring hepatic stemness.Figure 41a3-iHepSCs Are Transcriptionally Closer Than 1b3-iHepSCs to LEPCs(A) RT-PCR analysis comparing the expression pattern of hepatocyte-, cholangiocyte-, and HepSC-specific markers in three independent clonal lines from 1a3- and 1b3-iHepSCs, which were generated by fluorescence-activated cell sorting with EPCAM.(B) Heatmap analysis describing whole-genome expression profiles of 1a3- and 1b3-iHepSCs at passage 10. Hierarchical clustering analysis based on the expression profiles from the heatmap is depicted at the top. MEFs and LEPCs were used as negative and positive controls, respectively.(C) TRNs in 1a3- and 1b3-iHepSCs. Yellow and red dashed circles represent MEF- and LEPC-specific modules, respectively.(D and E) Heatmap (D) and PCA (E) describing the gene expression profiles of the LEPC-specific module in iHepSCs. Hierarchical clustering results are displayed on top of the heatmap. MEFs and LEPCs were used as negative and positive controls, respectively.(F and G) GO enrichment analysis of each iHepSC-specific DEGs.

We also performed TRN analysis by applying both the 1a3- and 1b3-specific DEGs defined from the established iHepSC lines onto the HepSC-TRN ([Figure 4](#fig4){ref-type="fig"}C). Consistent with our expression profiling ([Figures 4](#fig4){ref-type="fig"}A and 4B), the expression levels of genes associated with LEPC-specific modules were significantly higher in 1a3-iHepSCs than in 1b3-iHepSCs, resulting in the relatively closer clustering of LEPCs and 1a3-iHepSCs ([Figure 4](#fig4){ref-type="fig"}D). Principal component analysis also showed that the expression pattern of the LEPC-specific module in 1a3-iHepSCs is very similar to that in LEPCs ([Figure 4](#fig4){ref-type="fig"}E). To our surprise, GO analysis showed that 1a3-specific DEGs were all associated with typical hepatic features, such as distinct metabolic processes ([Figure 4](#fig4){ref-type="fig"}F). However, non-hepatic events were highly ranked in 1b3-DEGs ([Figure 4](#fig4){ref-type="fig"}G), supporting the notion that 1b3 activates subsets of genes that do not belong to the hepatic lineage. Taken together, our data indicate that *Hnf1α* is indeed a master factor for inducing hepatic stemness.

Hnf1a Dramatically Enhances *In Vitro* Differentiation Potential of iHepSCs into Cholangiocytes {#sec2.5}
-----------------------------------------------------------------------------------------------

To investigate the effect of *Hnf1α* and *Hnf1β* on the functionality of iHepSCs, we compared the *in vitro* differentiation potential of the two iHepSC lines. Following 7 days of differentiation into hepatocytes, both iHepSC lines had formed typical aggregates and exhibited increased expression of mature hepatic genes but reduced expression of both cholangiocyte- and stem cell-specific markers ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A--S5D). Moreover, the genes associated with drug transport activity as well as the CYP450 genes were significantly increased to a similar extent ([Figures 5](#fig5){ref-type="fig"}E and 5F). The additional set of *in vitro* functional studies clearly suggests that the iHepSC lines from two distinct combinations are comparable in their hepatic differentiation capacity ([Figures 5](#fig5){ref-type="fig"}B--5E).Figure 51a3-iHepSCs Exhibit Enhanced Differentiation Potential into Cholangiocytes(A) Expression of hepatocyte- and cholangiocyte-specific markers was analyzed by qPCR after 7 days of differentiation of iHepSCs. All the values were normalized to those of MEFs and are presented as mean ± SD of triplicate values from three biological replicates. Paired t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01.(B and C) *In vitro* functional analyses of iHepSC-derived hepatocytes by PAS staining (B) and ICG uptake assay (C). Scale bars, 100 μm.(D and E) Comparison of secretion levels of serum albumin (D) and urea (E) from iHepSC-derived hepatocytes. MEFs and primary hepatocytes were used as negative and positive controls, respectively. Data are presented as mean ± SD of triplicate values.(F) Immunostaining images of F-actin in iHepSC-derived ductal cysts. Nuclei were stained with DAPI. Scale bars, 100 μm.(G) Transport of Rho123 into the central lumen of a ductal cyst derived from iHepSCs. Scale bars, 100 μm.(H and I) Image representation (H) and number (I) of Rho123-transporting cysts in the culture dish after 7 days of differentiation of iHepSCs. Three biological replicates of iHepSCs at passage 10 were used for the analysis. Data are presented as mean ± SD from three different experiments. Two-tailed Student's t test: ^∗∗^p \< 0.01. Scale bars, 100 μm.(J) Expression of genes related to functional cholangiocytes was analyzed by qPCR. All the values were normalized to those of bile duct tissues as a positive control and are presented as mean ± SD of triplicate values from three biological replicates. Two-tailed Student's t test: ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.

Next, we compared the differentiation potential of these two iHepSC lines into cholangiocytes. Although both 1a3- and 1b3-iHepSCs had formed cysts with typical apicobasal polarity under the 3D culture conditions ([Figure 5](#fig5){ref-type="fig"}F), their differentiation efficiency into cholangiocytes was dramatically different ([Figures 5](#fig5){ref-type="fig"}G and 5H). Indeed, 1a3-iHepSCs exhibited significantly increased numbers of Rho123-transporting mature cysts (8.6-fold higher) compared with 1b3-iHepSCs ([Figure 5](#fig5){ref-type="fig"}I). Furthermore, 1a3-iHepSC-derived cholangiocytes strongly expressed cholangiocyte markers to the level similar to that of bile duct tissues ([Figure 5](#fig5){ref-type="fig"}J). However, 1b3-iHepSC-derived cholangiocytes displayed relatively weak or no expression of those markers ([Figure 5](#fig5){ref-type="fig"}J). These data indicate that *Hnf1α* plays a crucial role as a determinant of hepatic stemness, resulting in the generation of iHepSCs with a dramatically enhanced cholangiocyte differentiation potential.

Notch Signaling-Mediated Secondary Conversion into Cholangiocyte Progenitor-like Cells {#sec2.6}
--------------------------------------------------------------------------------------

Interestingly, 1a3-iHepSCs from different passages (P10 and P30) displayed distinct differentiation efficiency toward mature cholangiocytes ([Figure S6](#mmc1){ref-type="supplementary-material"}A). In contrast, their hepatic differentiation was dramatically reduced upon further passaging, and completely abolished in 1a3-iHepSCs from P30 ([Figure S6](#mmc1){ref-type="supplementary-material"}B). To understand these distinct passage-dependent differentiation patterns of 1a3-iHepSCs toward cholangiocytes and hepatocytes, we determined the expression levels of hepatocyte and cholangiocyte markers. Although 1a3-iHepSCs from later passages (P20 and P30) displayed dramatically reduced levels of hepatocyte markers ([Figures 6](#fig6){ref-type="fig"}A and 6B), expression levels of cholangiocyte markers including *CK19*, *Aqp1*, *Cftr*, *Ggt*, and *Hnf β* were stably maintained or further enhanced even after long-term passaging ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}C), indicating that prolonged *in vitro* culture could induce further commitment of 1a3-iHepSCs into iCPCs, which predominantly differentiate into mature cholangiocytes ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). However, 1b3-iHepSCs maintained their hepatic stemness even after long-term culture ([Figure 6](#fig6){ref-type="fig"}A), suggesting that the secondary conversion of iHepSCs into iCPCs is mediated by 1a3 but not 1b3. This unique property of 1a3-iHepSCs offers a two-step strategy for generating iCPCs.Figure 6Notch-Mediated Secondary Conversion of 1a3-iHepSCs into Cholangiocyte Progenitor-like Cells(A) Expression patterns of markers were evaluated in iHepSC lines from different passages by qPCR. All values were normalized to those of MEFs and are presented as mean ± SD from four biological replicates at each passage. Paired t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(B) Immunofluorescence of 1a3-iHepSCs at different passages. Scale bar, 100 μm.(C and D) Expression of hepatocyte-specific (C) and cholangiocyte-specific (D) markers in 1a3-iHepSCs was measured by qPCR. 1a3-iHepSCs were cultured in the absence or presence of 20 nM DAPT, a γ-secretase inhibitor of Notch signaling, during 10 serial passages from P1 to P10 (P10) and from P10 to 20 (P20). All values were normalized to those of MEFs and are presented as mean ± SD from three biological replicates. Paired t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01; n.s., not significant.(E) Immunofluorescence of iHepSCs cultured in the absence or presence of 20 nM DAPT. Scale bar, 100 μm.(F) Graphical abstract describing two-step conversion strategy for generating iCPCs. Fibroblasts were converted primarily to bipotential hepatic stem cells by the ectopic expression of defined factors *Hnf1α* and *Foxa3*, then subjected to a secondary conversion process toward unipotent CPCs by spontaneous activation of Notch signaling.

Recent studies have described Notch signaling-mediated differentiation of human PSCs into CPCs or mature cholangiocytes ([@bib9], [@bib26], [@bib29]). Thus we next investigated whether the secondary conversion of 1a3-iHepSCs into iCPCs is also governed by Notch signaling. As a result, we found that the expression levels of Notch and its targets (*Notch2*, *Jag1*, and *Hes1*) were increased upon serial passaging of 1a3-iHepSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}C). However, the expression levels of all the hepatic markers were stably maintained in 1a3-iHepSCs in the presence of DAPT, a γ-secretase inhibitor that blocks Notch signaling *in vitro* ([Figures 6](#fig6){ref-type="fig"}C--6E). Furthermore, the differentiation of 1a3-iCPCs (at P20) into mature cholangiocytes was completely blocked by DAPT treatment ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6F). Taken together, our data indicate that the secondary conversion process of iHepSCs into iCPCs as well as the unipotential differentiation potential of iCPCs into mature cholangiocytes are determined by Notch signaling ([Figure 6](#fig6){ref-type="fig"}F).

To further investigate the *in vivo* functionality of 1a3-iCPCs, we used 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice, a well-known model for activation of liver progenitor cells and bile duct proliferation ([@bib28]), which allow for the spontaneous differentiation of liver progenitor cells into cholangiocytes. 1 × 10^6^ GFP-labeled 1a3-iCPCs (P20) with normal karyotype ([Figure S7](#mmc1){ref-type="supplementary-material"}A) were transplanted into DDC-fed mice via intrasplenic injection. After 4 weeks of transplantation, the 1a3-iCPCs had not only incorporated into pre-existing bile ducts but also newly formed a significant number of GFP^+^ ductal structures through bile ductular proliferation without forming tumor ([Figures 7](#fig7){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}B). However, only a few GFP^+^ ductal structures were observed in the liver sections of mice transplanted with 1b3-iHepSCs that had been maintained under the same culture conditions as the 1a3-iCPCs ([Figure 7](#fig7){ref-type="fig"}A). We compared the differentiation efficiency of both cell lines by counting the number of GFP^+^ cholangiocytes per total number of cholangiocytes. The number of GFP^+^ ductal structures derived from 1a3-iCPCs was significantly higher than that from 1b3-iHepSCs ([Figure 7](#fig7){ref-type="fig"}B), although the *in vivo* hepatic differentiation potential of 1b3-iHepSCs overwhelmingly exceeds that of 1a3-iCPCs ([Figures S7](#mmc1){ref-type="supplementary-material"}C and S7D). Furthermore, a larger number of most GFP^+^ 1a3-iCPC-derived cells strongly expressed CK19 and the functional cholangiocyte-specific marker osteopontin (OPN), compared with 1b3-iHepSC-derived cells ([Figures 7](#fig7){ref-type="fig"}C--7F). Collectively, these results clearly demonstrate that iCPCs that had converted from 1a3-iHepSCs via Notch signaling pathway are functionally mature.Figure 7Robust Differentiation of 1a3-iCPCs into Mature Cholangiocytes(A) Following transplantation, the engrafted GFP-labeled iCPCs and iHepSCs were differentiated into cholangiocytes (red arrowheads) in the bile ducts of livers of DDC-fed mice. Scale bars, 100 μm.(B) Efficiency of differentiation into cholangiocytes was measured by counting the number of GFP^+^ cholangiocytes per total number of cholangiocytes in the liver sections (1a3-iCPCs: 58.9% ± 5.9% versus 1b3-iHepSCs: 2.9% ± 5.0%). Data are presented as mean ± SD from three independent samples. Two-tailed Student's t test: ^∗∗∗^p \< 0.001.(C--F) The GFP^+^ cells in the bile ducts expressed mature cholangiocyte markers, CK19 (C and D) and OPN (E and F), as shown by immunohistochemistry. The images were obtained from serially sectioned slides. Scale bars, 100 μm.

Discussion {#sec3}
==========

To maintain several metabolic functions, the liver consists of a few cell types that play distinct roles in hepatic homeostasis ([@bib1]). Although parenchymal hepatocytes make up more than 85% of the liver, non-parenchymal cell types are known to be involved in liver regeneration ([@bib24]). Indeed, several cholangiocyte-related diseases such as cystic fibrosis, Alagille syndrome, and primary sclerosing cholangitis exhibit severe liver dysfunction caused by abnormality in the bile ducts ([@bib16], [@bib22], [@bib34]), indicating the need for a novel approach for obtaining functional cholangiocytes with high purity. For this, [@bib38] demonstrated the direct generation of iHepSCs from mouse fibroblasts using *Hnf1β* and *Foxa3*. Although the previous study clearly characterized the bipotency of the iHepSCs, the conversion efficiency into iHepSCs was too low (less than 0.5%), with unusually extremely low differentiation potential into cholangiocytes (less than 2%). In the current study, we found that the combination of *Hnf1α* and *Foxa3* is sufficient for the robust generation of bipotential iHepSCs with 3.2- to 6.8-fold increased conversion efficiency compared with the previously defined combination ([Figure 3](#fig3){ref-type="fig"}). Throughout our mechanistic and functional studies, we observed that 1a3-iHepSCs are superior to 1b3-derived iHepSCs in their gene expression profile ([Figures 4](#fig4){ref-type="fig"}A, 4B, and 4D), conversion kinetics ([Figures 3](#fig3){ref-type="fig"}C and 3D), and both *in vitro* and *in vivo* differentiation potential into cholangiocytes ([Figures 5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}), indicating that *Hnf1α* is a master factor for inducing hepatic stemness in somatic cells.

Previous *in vivo* studies might indirectly suggest a distinct role for each transcription factor (*Hnf1α*, *Hnf1β*, and *Foxa3*) in the generation of iHepSCs. *Foxa3* is a pioneer factor that belongs to the Foxa subfamily of winged helix/forkhead box transcription factors, which are known to guide many transcription factors in accessing their targets during liver development and regeneration ([@bib14], [@bib17], [@bib37]), suggesting its potential and essential role in iHepSC generation. However, *Hnf1β* is essential for the earliest step of hepatic bud formation, as its depletion leads the embryonic lethality ([@bib4], [@bib23]), indicating that *Hnf1β* plays a critical role in early liver development. In contrast, *Hnf1α* is known to play a critical role in liver regeneration ([@bib7], [@bib18], [@bib25]), despite its dispensable role in liver development ([@bib27]). Upon liver injury, HNF1A is known to directly bind to STAT3 and AP-1, resulting in the activation of several regeneration-associated hepatic genes ([@bib18]), suggesting that *Hnf1α* plays a key role in liver regeneration. Importantly, *Hnf1α*, together with *Foxa3*, is activated specifically during oval cell proliferation; oval cells are the prototype adult liver progenitor cell population ([@bib7], [@bib25]). Indeed, in the adult livers undergoing rapid regeneration process after 70% partial hepatectomy (PHx), the expression of *Hnf1α* preceded that of *Hnf1β*; *Hnf1α* was immediately activated after PHx, while *Hnf1β* was slowly and progressively upregulated ([Figure S7](#mmc1){ref-type="supplementary-material"}E). Considering that *Hnf1α* and *Foxa3* together lead the robust induction of hepatic stemness ([Figure 3](#fig3){ref-type="fig"}), 1a3-mediated direct conversion process toward an iHepSC state may share a similar pathway with the *in vivo* liver regeneration event that is orchestrated by both *Hnf1α* and *Foxa3*.

Furthermore, prolonged *in vitro* culture of 1a3-iHepSCs could induce the Notch signaling-mediated secondary conversion of 1a3-iHepSCs into unipotent iCPCs. Upon *in vitro* differentiation of 1a3-iCPCs into mature cholangiocytes, we observed bile duct proliferation ([Figure S7](#mmc1){ref-type="supplementary-material"}F), a typical regenerative response to liver injury ([@bib35]), suggesting that 1a3-iCPCs hold clinical potential for modeling various forms of liver diseases caused by cholangiocyte dysfunction. Further efforts in generating human iHepSCs/iCPCs and applying this technology for modeling genetic cholangiocyte-related diseases would essentially be required for successfully translating iHepSC/iCPC technology to the clinic.

Experimental Procedures {#sec4}
=======================

Mice and Derivation of Fibroblasts {#sec4.1}
----------------------------------

All mice used were bred and housed at the mouse facility of Konkuk University (KU) or at the Chinese Academy of Science (CAS). Animal handling was in accordance with both the KU and CAS animal protection guidelines. MEFs were derived on embryonic day 13.5 after removing the head and all internal organs, including the liver, from C57/B6 mouse strain embryos, and were cultured in DMEM (Hyclone) containing 10% fetal bovine serum and 5 mL of penicillin/streptomycin/glutamine (Invitrogen).
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